Zelluna Immunotherapy

Zelluna Immunotherapy AS is a privately owned biopharmaceutical company founded in 2016 focused on developing transformative T cell receptor (TCR) based cellular immunotherapies for the treatment of cancers. The goal of the company is reflected in its vision:

“Saving life through innovative cancer-targeted cell therapies”

To achieve this and provide benefit to patients and their families, its are developing TCR guided cell therapies deploying a mechanism of action that is believed to have the potential to be both safer and more potent at the same time. Its also developing therapies based on the effector functions of autologous T cells (TCR-T) and allogeneic NK cells (TCR-NK). Both of these platforms have their unique advantages and gives the opportunity to attack cancers from multiple angles and improve access to these advanced therapies to a large patient population.

In order to advance our therapies most efficiently towards the clinic and patients, we are making use of already existing competence and infrastructure, and we have an extensive network of industrial and academic partners. In addition to executing on established programs, its constantly exploring ways of expanding and optimizing our future product pipeline to the benefit of patients.

Zelluna is led by an experienced international management team and the company is located at the Oslo Cancer Cluster Innovation Park, in close proximity to the Norwegian Radium Hospital/Oslo University Hospital.